Expression and significance of androgen receptor in triple negative breast cancer of Xinjiang_CHINESE JOURNAL OF BASES AND CLINICS IN GENERAL SURGERY

Authors：

DENG Feng , Adilijiang·Maimaitiming , LUAN Zheyao ,  Dilimulati·Aisimutula

Department of Breast Surgery, The First Affiliated Hospital of Xinjiang Medical University, Urumqi 830054, P. R. China;

Corresponding author：

Dilimulati·Aisimutula, Email: 2499156828@qq.com

Keywords：

triple negative breast cancer; androgen receptor; clinicopathologic feature

DOI：

10.7507/1007-9424.201705027

Video：

Export PDF Favorites Scan Get Citation

Abstract Full text Figures/Tables Video References Cited by

Objective To investigate relationship between androgen receptor (AR) and clinicopathologic features of patients with triple negative breast cancer (TNBC) in Xinjiang. Methods The clinical data of Han and Uygur patients with TNBC from the First Affiliated Hospital of Xinjiang Medical University from December 2012 to December 2016 were retrospectively analyzed. And the expression of the AR and the clinicopathologic features of the patients with TNBC were extracted. The results were analyzed by SPSS 19.0. Results A total of 178 patients with TNBC were included, including 127 Han and 51 Uygur patients. The positive rate of the AR expression in the 178 patients with TNBC was 21.3% (38/178), which was significantly related to the expression of Ki-67 (χ²=15.196, P<0.001), was not related to the ethnicity (χ²=0.203, P=0.688), age (χ²=0.221, P=0.715), tumor size (χ²=0.047, P=0.855), lymph node status (χ²=0.874, P=0.354), or histological grade (χ²=0.001, P=1.000). And there were no statistically significant differences in the clinicopathologic features between the Han patients with TNBC and the Uygur patients with TNBC. Conclusion AR positive expression is related to Ki-67, but clinicopathologic features have no significant differences between Han and Uygur patients with TNBC in Xingjinag.

Citation： DENG Feng, Adilijiang·Maimaitiming, LUAN Zheyao, Dilimulati·Aisimutula. Expression and significance of androgen receptor in triple negative breast cancer of Xinjiang. CHINESE JOURNAL OF BASES AND CLINICS IN GENERAL SURGERY, 2017, 24(11): 1353-1356. doi: 10.7507/1007-9424.201705027 Copy

1.	Locatelli MA, Curigliano G, Eniu A. Extended adjuvant chemotherapy in triple-negative breast cancer. Breast Care (Basel), 2017, 12(3): 152-158.
2.	Perou CM, Sørlie T, Eisen MB, et al. Molecular portraits of human breast tumours. Nature, 2000, 406(6797): 747-752.
3.	Vona-Davis L, Rose DP, Hazard H, et al. Triple-negative breast cancer and obesity in a rural Appalachian population. Cancer Epidemiol Biomarkers Prev, 2008, 17(12): 3319-3324.
4.	Carey LA, Perou CM, Livasy CA, et al. Race, breast cancer subtypes, and survival in the Carolina Breast Cancer Study. JAMA, 2006, 295(21): 2492-2502.
5.	Rakha EA, El-Rehim DA, Paish C, et al. Basal phenotype identifies a poor prognostic subgroup of breast cancer of clinical importance. Eur J Cancer, 2006, 42(18): 3149-3156.
6.	Kim JY, Jung HH, Ahn S, et al. The relationship between nuclear factor (NF)-κB family gene expression and prognosis in triple-negative breast cancer (TNBC) patients receiving adjuvant doxorubicin treatment. Sci Rep, 2016, 6: 31804.
7.	Kumar P, Aggarwal R. An overview of triple-negative breast cancer. Arch Gynecol Obstet, 2016, 293(2): 247-269.
8.	Lin HY, Sun M, Lin C, et al. Androgen-induced human breast cancer cell proliferation is mediated by discrete mechanisms in estrogen receptor-alpha-positive and-negative breast cancer cells. J Steroid Biochem Mol Biol, 2009, 113(3-5): 182-188.
9.	Wang C, Pan B, Zhu H, et al. Prognostic value of androgen receptor in triple negative breast cancer: A meta-analysis. Oncotarget, 2016, 7(29): 46482-46491.
10.	郑乔丹, 吴文苑. 雄激素受体对人乳腺癌细胞侵袭和迁移影响的研究. 实用医学杂志, 2014, 30(8): 1189-1193.
11.	李铁灵, 郭海峰, 孙治国. 三阴性年轻乳腺癌患者雄激素受体表达与瘤体大小、淋巴转移的相关性研究. 现代肿瘤医学, 2015, 23(10): 1361-1363.
12.	Foulkes WD, Stefansson IM, Chappuis PO, et al. Germline BRCA1 mutations and a basal epithelial phenotype in breast cancer. J Natl Cancer Inst, 2003, 95(19): 1482-1485.
13.	Rakha EA, El-Sayed ME, Green AR, et al. Prognostic markers in triple-negative breast cancer. Cancer, 2007, 109(1): 25-32.
14.	Higgins MJ, Wolff AC. The androgen receptor in breast cancer: learning from the past. Breast Cancer Res Treat, 2010, 124(3): 619-621.
15.	Gasparini P, Fassan M, Cascione L, et al. Androgen receptor status is a prognostic marker in non-basal triple negative breast cancers and determines novel therapeutic options. PLoS One, 2014, 9(2): e88525.
16.	Mohammadizadeh F, Sajadieh S, Sajjadieh H, et al. Androgen receptor expression and its relationship with clinicopathological parameters in an Iranian population with invasive breast carcinoma. Adv Biomed Res, 2014, 3: 132.
17.	杨君, 马学真. AR 和 Ki-67 在三阴性乳腺癌中的表达及临床意义. 青岛大学, 2014: 1-41.
18.	李中琦, 郑怡, 滕晓东, 等. CK5/6 和 AR 在三阴性乳腺癌中的表达及其与临床病理特征的联系. 浙江医学, 2009, 31(1): 49-51.
19.	Asano Y, Kashiwagi S, Goto W, et al. Expression and clinical significance of androgen receptor in triple-negative breast cancer. Cancers (Basel), 2017, 9(1). pii: E4.
20.	McNamara KM, Yoda T, Miki Y, et al. Androgenic pathway in triple negative invasive ductal tumors: its correlation with tumor cell proliferation. Cancer Sci, 2013, 104(5): 639-646.
21.	Ricciardi GR, Adamo B, Ieni A, et al. Androgen receptor (AR), E-cadherin, and Ki-67 as emerging targets and novel prognostic markers in triple-negative breast cancer (TNBC) patients. PLoS One, 2015, 10(6): e0128368.
22.	Kim Y, Jae E, Yoon M. Influence of androgen receptor expression on the survival outcomes in breast cancer: a meta-analysis. J Breast Cancer, 2015, 18(2): 134-142.
23.	Collina F, Cerrone M, Peluso V, et al. Downregulation of androgen receptor is strongly associated with diabetes in triple negative breast cancer patients. Am J Transl Res, 2016, 8(8): 3530-3539.
24.	Barnard ME, Boeke CE, Tamimi RM. Established breast cancer risk factors and risk of intrinsic tumor subtypes. Biochim Biophys Acta, 2015, 1856(1): 73-85.
25.	张继运, 李飞, 沙新海, 等. 新疆汉族与维吾尔族三阴性乳腺癌临床病理特征对比分析. 山东医药, 2012, 52(40): 85-86.

1. Locatelli MA, Curigliano G, Eniu A. Extended adjuvant chemotherapy in triple-negative breast cancer. Breast Care (Basel), 2017, 12(3): 152-158.
2. Perou CM, Sørlie T, Eisen MB, et al. Molecular portraits of human breast tumours. Nature, 2000, 406(6797): 747-752.
3. Vona-Davis L, Rose DP, Hazard H, et al. Triple-negative breast cancer and obesity in a rural Appalachian population. Cancer Epidemiol Biomarkers Prev, 2008, 17(12): 3319-3324.
4. Carey LA, Perou CM, Livasy CA, et al. Race, breast cancer subtypes, and survival in the Carolina Breast Cancer Study. JAMA, 2006, 295(21): 2492-2502.
5. Rakha EA, El-Rehim DA, Paish C, et al. Basal phenotype identifies a poor prognostic subgroup of breast cancer of clinical importance. Eur J Cancer, 2006, 42(18): 3149-3156.
6. Kim JY, Jung HH, Ahn S, et al. The relationship between nuclear factor (NF)-κB family gene expression and prognosis in triple-negative breast cancer (TNBC) patients receiving adjuvant doxorubicin treatment. Sci Rep, 2016, 6: 31804.
7. Kumar P, Aggarwal R. An overview of triple-negative breast cancer. Arch Gynecol Obstet, 2016, 293(2): 247-269.
8. Lin HY, Sun M, Lin C, et al. Androgen-induced human breast cancer cell proliferation is mediated by discrete mechanisms in estrogen receptor-alpha-positive and-negative breast cancer cells. J Steroid Biochem Mol Biol, 2009, 113(3-5): 182-188.
9. Wang C, Pan B, Zhu H, et al. Prognostic value of androgen receptor in triple negative breast cancer: A meta-analysis. Oncotarget, 2016, 7(29): 46482-46491.
10. 郑乔丹, 吴文苑. 雄激素受体对人乳腺癌细胞侵袭和迁移影响的研究. 实用医学杂志, 2014, 30(8): 1189-1193.
11. 李铁灵, 郭海峰, 孙治国. 三阴性年轻乳腺癌患者雄激素受体表达与瘤体大小、淋巴转移的相关性研究. 现代肿瘤医学, 2015, 23(10): 1361-1363.
12. Foulkes WD, Stefansson IM, Chappuis PO, et al. Germline BRCA1 mutations and a basal epithelial phenotype in breast cancer. J Natl Cancer Inst, 2003, 95(19): 1482-1485.
13. Rakha EA, El-Sayed ME, Green AR, et al. Prognostic markers in triple-negative breast cancer. Cancer, 2007, 109(1): 25-32.
14. Higgins MJ, Wolff AC. The androgen receptor in breast cancer: learning from the past. Breast Cancer Res Treat, 2010, 124(3): 619-621.
15. Gasparini P, Fassan M, Cascione L, et al. Androgen receptor status is a prognostic marker in non-basal triple negative breast cancers and determines novel therapeutic options. PLoS One, 2014, 9(2): e88525.
16. Mohammadizadeh F, Sajadieh S, Sajjadieh H, et al. Androgen receptor expression and its relationship with clinicopathological parameters in an Iranian population with invasive breast carcinoma. Adv Biomed Res, 2014, 3: 132.
17. 杨君, 马学真. AR 和 Ki-67 在三阴性乳腺癌中的表达及临床意义. 青岛大学, 2014: 1-41.
18. 李中琦, 郑怡, 滕晓东, 等. CK5/6 和 AR 在三阴性乳腺癌中的表达及其与临床病理特征的联系. 浙江医学, 2009, 31(1): 49-51.
19. Asano Y, Kashiwagi S, Goto W, et al. Expression and clinical significance of androgen receptor in triple-negative breast cancer. Cancers (Basel), 2017, 9(1). pii: E4.
20. McNamara KM, Yoda T, Miki Y, et al. Androgenic pathway in triple negative invasive ductal tumors: its correlation with tumor cell proliferation. Cancer Sci, 2013, 104(5): 639-646.
21. Ricciardi GR, Adamo B, Ieni A, et al. Androgen receptor (AR), E-cadherin, and Ki-67 as emerging targets and novel prognostic markers in triple-negative breast cancer (TNBC) patients. PLoS One, 2015, 10(6): e0128368.
22. Kim Y, Jae E, Yoon M. Influence of androgen receptor expression on the survival outcomes in breast cancer: a meta-analysis. J Breast Cancer, 2015, 18(2): 134-142.
23. Collina F, Cerrone M, Peluso V, et al. Downregulation of androgen receptor is strongly associated with diabetes in triple negative breast cancer patients. Am J Transl Res, 2016, 8(8): 3530-3539.
24. Barnard ME, Boeke CE, Tamimi RM. Established breast cancer risk factors and risk of intrinsic tumor subtypes. Biochim Biophys Acta, 2015, 1856(1): 73-85.
25. 张继运, 李飞, 沙新海, 等. 新疆汉族与维吾尔族三阴性乳腺癌临床病理特征对比分析. 山东医药, 2012, 52(40): 85-86.

CHINESE JOURNAL OF BASES AND CLINICS IN GENERAL SURGERY

Expression and significance of androgen receptor in triple negative breast cancer of Xinjiang

Abstract Full text Figures/Tables Video References Cited by

Previous Article

Next Article

Format

Content